

Arlene O Siefker-Radtke

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5424627/arlene-o-siefker-radtke-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

8,912
citations

47
h-index

94
g-index

137
ext. papers

11,172
ext. citations

6.6
avg, IF

5.72
L-index

#	Paper	IF	Citations
125	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2017 , 18, 312-322	21.7	981
124	Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. <i>Cancer Cell</i> , 2014 , 25, 152-65	24.3	977
123	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 381, 338-348	59.2	456
122	miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 5060-72	12.9	353
121	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020 , 77, 420-433	10.2	309
120	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009 , 28, 335-44	9.6	272
119	Focus on bladder cancer. <i>Cancer Cell</i> , 2004 , 6, 111-6	24.3	221
118	Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. <i>Cancer</i> , 2007 , 110, 62-7	6.4	220
117	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014 , 11, 400-10	5.5	189
116	Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. <i>Journal of Urology</i> , 2003 , 169, 1295-8	2.5	189
115	Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. <i>Journal of Urology</i> , 2004 , 172, 481-4	2.5	180
114	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. <i>Cancer</i> , 2010 , 116, 3127-34	6.4	174
113	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1240-1267	7.3	172
112	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. <i>EBioMedicine</i> , 2016 , 12, 105-117	8.8	169
111	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2014 , 66, 255-62	10.2	163
110	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 429-40	2.8	160
109	Frequent truncating mutations of STAG2 in bladder cancer. <i>Nature Genetics</i> , 2013 , 45, 1428-30	36.3	139

108	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. <i>European Urology</i> , 2013 , 63, 58-66	10.2	133
107	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 1794-9	6.4	132
106	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 1041-1053	7.3	128
105	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. <i>Nature Communications</i> , 2018 , 9, 3503	17.4	124
104	Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. <i>Journal of Urology</i> , 2014 , 191, 40-7	2.5	122
103	Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2592-7	2.2	120
102	Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. <i>Journal of Urology</i> , 2006 , 175, 2058-62	2.5	109
101	Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. <i>Journal of Urology</i> , 2004 , 171, 145-8	2.5	109
100	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1608-1616	2.2	108
99	Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. <i>Journal of Urology</i> , 2013 , 189, 1656-61	2.5	107
98	The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. <i>Clinical Cancer Research</i> , 2010 , 16, 4461-7	12.9	107
97	Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. <i>European Urology</i> , 2013 , 64, 307-13	10.2	106
96	The p63 protein isoform $\Delta p63$ inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. <i>Journal of Biological Chemistry</i> , 2013 , 288, 3275-88	5.4	95
95	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. <i>European Urology</i> , 2016 , 70, 611-620	10.2	92
94	Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. <i>Clinical Cancer Research</i> , 2008 , 14, 1478-86	12.9	85
93	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 2684-93	6.4	79
92	Urachal adenocarcinoma: a clinician's guide for treatment. <i>Seminars in Oncology</i> , 2012 , 39, 619-24	5.5	73
91	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1213-1224	7.3	73

90	Urachal carcinoma: surgical and chemotherapeutic options. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 1715-21	3.5	72
89	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020 , 26, 1845-1851	50.5	72
88	Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. <i>Cancer</i> , 2007 , 110, 764-9	6.4	70
87	A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. <i>Cancer</i> , 2013 , 119, 540-7	6.4	63
86	Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1361-7	2.2	61
85	p63 expression defines a lethal subset of muscle-invasive bladder cancers. <i>PLoS ONE</i> , 2012 , 7, e30206	3.7	58
84	Urachal carcinoma: a pathologic and clinical study of 46 cases. <i>Human Pathology</i> , 2015 , 46, 1808-14	3.7	54
83	Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. <i>Urology</i> , 2009 , 73, 147-52	1.6	53
82	P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. <i>European Urology</i> , 2007 , 52, 769-74	10.2	52
81	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. <i>Nature Reviews Urology</i> , 2018 , 15, 112-124	5.5	52
80	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019 , 76, 599-603	10.2	50
79	A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. <i>Journal of Urology</i> , 2008 , 180, 867-72; discussion 872	2.5	50
78	Bladder cancer: narrowing the gap between evidence and practice. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5680-4	2.2	47
77	Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 377-94, x-xi	3.1	45
76	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4503-4503	2.2	42
75	Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. <i>Urology</i> , 2011 , 78, 61-7	1.6	37
74	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. <i>American Journal of Clinical Pathology</i> , 2017 , 147, 500-506	1.9	36
73	Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. <i>Clinical Cancer Research</i> , 2020 , 26, 5120-5128	12.9	36

72	Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2006 , 107, 2254-61	6.4	35
71	Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 59.e1-8	2.8	33
70	Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 879-85	2.8	31
69	Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. <i>PLoS ONE</i> , 2013 , 8, e69509	3.7	30
68	Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. <i>Journal of Urology</i> , 2018 , 199, 1129-1142	2.5	28
67	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. <i>Oncotarget</i> , 2016 , 7, 80164-80174	3.3	28
66	FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4511-4511	2.2	27
65	Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. <i>Human Pathology</i> , 2018 , 79, 57-65	3.7	27
64	A Phase I Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. <i>Molecular Therapy</i> , 2016 , 24, 1484-91	11.7	26
63	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. <i>BJU International</i> , 2017 , 119, 684-691	5.6	24
62	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. <i>World Journal of Urology</i> , 2017 , 35, 327-335	4	23
61	Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 261-261 ^{2.2}	2.2	22
60	Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. <i>Canadian Urological Association Journal</i> , 2009 , 3, S228-31	1.2	21
59	Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	18
58	Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 1089-1098	4.2	17
57	Perioperative chemotherapy for upper tract urothelial cancer. <i>Nature Reviews Urology</i> , 2012 , 9, 266-73	5.5	17
56	NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 388-388	2.2	16
55	p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. <i>Cancer Biology and Therapy</i> , 2012 , 13, 477-86	4.6	14

54	Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. <i>Frontiers in Oncology</i> , 2021 , 11, 621591	5.3	14
53	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021 , 127, 840-849	6.4	14
52	Optimizing management of upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 492-498	2.8	12
51	The role of radical cystectomy in patients with clinical T4b bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 157-61	2.8	12
50	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 95-105	4	12
49	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. <i>Nature Communications</i> , 2021 , 12, 5606	17.4	12
48	Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. <i>Cancer</i> , 2006 , 107, 497-505	6.4	11
47	Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. <i>Urology</i> , 2016 , 89, 83-9	1.6	10
46	Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. <i>Cancer</i> , 2013 , 119, 1994-8	6.4	10
45	Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. <i>European Urology Focus</i> , 2017 , 3, 577-583	5.1	10
44	Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. <i>Urology</i> , 2017 , 102, 7-16	1.6	10
43	Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4513-4513	2.2	10
42	Targeting advanced urothelial carcinoma-developing strategies. <i>Current Opinion in Oncology</i> , 2019 , 31, 207-215	4.2	10
41	Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. <i>BJU International</i> , 2018 , 122, 89-98	5.6	9
40	Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275 2018 ,		9
39	Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 450-450	2.2	9
38	Systemic chemotherapy options for metastatic bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 877-85	3.5	8
37	Neoadjuvant chemotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 464-7	2.8	8

36	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021 , 17, 3137-3150	3.6	8
35	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. <i>IScience</i> , 2020 , 23, 101206.1	6.1	7
34	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. <i>European Urology Focus</i> , 2018 , 4, 442-454	5.1	6
33	Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 218-24	3.3	6
32	Bladder cancer: can we move beyond chemotherapy?. <i>Current Oncology Reports</i> , 2010 , 12, 278-83	6.3	6
31	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4571-TPS4571	2.2	6
30	Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 342-353	7.1	6
29	Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-11	7.1	5
28	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3346-8	2.2	5
27	Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 1701-3	3.5	5
26	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	5
25	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021 , 17, 137-149	3.6	5
24	Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 311-311	2.2	4
23	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. <i>Cancer Journal (Sudbury, Mass)</i> , 2016 , 22, 96-100	2.2	4
22	Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 354.e19-354.e26	2.8	3
21	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , 2021 ,	6.7	3
20	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021 , 19, 395-402	6.6	3
19	Towards effective adjuvant treatment for urothelial cancer. <i>Lancet Oncology, The</i> , 2015 , 16, 9-10	21.7	2

18	Uncommon Cancers of the Bladder 2012 , 23-33		2
17	Uncommon Cancers of the Bladder 2006 , 18-26		2
16	Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2021 , 206, 1258-1267	2.5	2
15	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events 2021 , 9,		2
14	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021 , 4, e2122998	10.4	2
13	High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. <i>Human Pathology</i> , 2017 , 67, 1263-1273		1
12	Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. <i>European Urology</i> , 2010 , 57, 728-9	10.2	1
11	A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4548-4548	2.2	1
10	A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 263-263	2.2	1
9	Emerging treatments in advanced urothelial cancer. <i>Current Opinion in Oncology</i> , 2020 , 32, 232-239	4.2	1
8	Uncommon Cancers of the Bladder 2017 , 41-53		0
7	Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.. <i>BJUI Compass</i> , 2022 , 3, 37-44	0.9	0
6	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.. <i>Nature Communications</i> , 2022 , 13, 1797	17.4	0
5	Reply to B. Biswas et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2097	2.2	
4	Bladder Cancer and Upper Tracts 2012 , 311-333		
3	Urachal and Non-urachal Adenocarcinomas of the Bladder 2016 , 139-151		
2	Small Cell Urothelial Carcinoma 2012 , 173-181		
1	Reply by Authors. <i>Journal of Urology</i> , 2021 , 206, 1267	2.5	

